KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Short term Debt (2016 - 2025)

Historic Short term Debt for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $4.3 billion.

  • Pfizer's Short term Debt fell 5563.46% to $4.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 billion, marking a year-over-year decrease of 5563.46%. This contributed to the annual value of $6.9 billion for FY2024, which is 3288.89% down from last year.
  • Per Pfizer's latest filing, its Short term Debt stood at $4.3 billion for Q3 2025, which was down 5563.46% from $4.3 billion recorded in Q2 2025.
  • Pfizer's 5-year Short term Debt high stood at $11.9 billion for Q2 2024, and its period low was $645.0 million during Q2 2022.
  • Moreover, its 5-year median value for Short term Debt was $4.3 billion (2025), whereas its average is $5.2 billion.
  • In the last 5 years, Pfizer's Short term Debt tumbled by 8517.92% in 2022 and then surged by 54930.23% in 2023.
  • Quarter analysis of 5 years shows Pfizer's Short term Debt stood at $2.2 billion in 2021, then skyrocketed by 31.41% to $2.9 billion in 2022, then soared by 251.44% to $10.4 billion in 2023, then plummeted by 32.89% to $6.9 billion in 2024, then crashed by 38.05% to $4.3 billion in 2025.
  • Its last three reported values are $4.3 billion in Q3 2025, $4.3 billion for Q2 2025, and $4.5 billion during Q1 2025.